Correction

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study

Torsak Bunupuradah1†, Ploenchan Chetchotisakd2†, Jintanat Ananworanich1,3,4, Warangkana Munsakul5, Supunnee Jiirajiriyavej6, Pacharee Kantipong7, Wisit Prasithsirikul8, Somnuek Sungkanuparp9, Chureeratana Bowonwanatunuwong10, Virat Klinbuayaem11, Stephen J Kerr1,12, Jiratchaya Sophonphan1, Sorakij Bhakecheep13, Bernard Hirschel14‡, Kiat Ruxrungtham1,4*,‡, the HIV STAR Study Group

1HIV-NAT, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
2KhonKaen University, KhonKaen, Thailand
3SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
4Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
5Faculty of Medicine, Vajira Hospital, University of Bangkok Metropolitan Administration, Bangkok, Thailand
6Taksin Hospital, Bangkok, Thailand
7Chiangrai Prachanukroh Hospital, Chiangrai, Thailand
8Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand
9Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
10Chonburi Hospital, Chonburi, Thailand
11Sanpatong Hospital, Chiang Mai, Thailand
12Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
13The National Health Security Office, Bangkok, Thailand
14Geneva University, Geneva, Switzerland

*Corresponding author e-mail: kiat.r@chula.ac.th
†These authors made an equal contribution to this work as joint first authors
‡These authors made an equal contribution to this work as senior authors

The publisher would like to report an omission from a recently published article [1]. The title of Figure 3 should contain ‘(A)’ and ‘(B)’, and the correct title and corresponding figure are shown. The publisher apologizes for this omission.

References

Figure 3. Baseline nucleoside-analogue resistance-associated mutations (A) and genotypic sensitivity scores (B) and their effect on virological control outcomes at week 48.

### A

<table>
<thead>
<tr>
<th>Resistance-associated mutation</th>
<th>LPV/r monotherapy</th>
<th>TDF/3TC/LPV/r</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TAM-1</td>
<td>82.4%</td>
<td>80%</td>
</tr>
<tr>
<td>Any TAM-2</td>
<td>75.4%</td>
<td>90.9%</td>
</tr>
<tr>
<td>3 TAM-2</td>
<td>72.2%</td>
<td>72.2%</td>
</tr>
<tr>
<td>M184V only</td>
<td>58.3%</td>
<td>74.4%</td>
</tr>
<tr>
<td>M184V+ any TAM-1</td>
<td>87.5%</td>
<td>84.5%</td>
</tr>
<tr>
<td>M184V+ any TAM-2</td>
<td>76.1%</td>
<td>92.7%</td>
</tr>
</tbody>
</table>

### B

<table>
<thead>
<tr>
<th>Number of active ARV(s) in the regimen</th>
<th>LPV/r monotherapy</th>
<th>GSS 1</th>
<th>GSS 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF/3TC/LPV/r arm</td>
<td>65.3%</td>
<td>79%</td>
<td>83.3%</td>
</tr>
</tbody>
</table>

*P<0.05, *P<0.05 compared with lopinavir/ritonavir (LPV/r) monotherapy. ARV, antiretroviral; GSS, genotypic sensitivity score; TAM, thymidine analogue mutation; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.

---

Accepted 25 October 2012; published online 26 October 2012